Skip to main content

Table 1 Demographics and patient characteristics of caregiver- and self-reported patients at baseline

From: Validation of the shortened Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS)

Characteristic

Caregiver-reported patients (3–26 years) n = 31

Self-reported patients (12–58 years) n = 20

Age category, n (%)

 3 to < 12 years

17

0

  ≥ 12 years

14

16b

Age in years, mean (SD)

10.8 (6.0)

22.5 (11.4)

Male, n (%)

31 (100)

20 (100)

Race, n (%)a

 White

27 (87.1)

16 (80.0)

 Black/African American

4 (12.9)

 Unknown

4 (20.0)

With MPS-affected siblings, n (%)

3 (9.7)

4 (20.0)

Age at diagnosis in years, mean (SD)

2.7 (1.5)

4.6 (3.0)c

Type of MPS II

 Severe (with CNS involvement)

20 (64.5)

1 (5)

 Attenuated (without CNS involvement)

10 (32.3)

15 (75)

 Unknown

1 (3.2)

4 (20.0)

Comorbidities, n (%)

 Cachexia

1 (3.2)

0

 Cardiac disease

17 (54.8)

11 (55.0)

 Carpal tunnel syndrome

19 (61.3)

15 (75.0)

 Convulsions

2 (6.5)

0

 Diarrhea

7 (22.6)

1 (5.0)

 Neurodegeneration

6 (19.4)

1 (5.0)

 Psychosocial problems

14 (45.2)

2 (10.0)

Severity of CI, n (%)

24 (77.4)

1 (5.0)d

 Mild

4 (16.7)

0

 Moderate

9 (37.5)

1 (5.0)

 Severe

11 (45.8)

0

  1. aNot mutually exclusive
  2. bFour patients have missing information
  3. c16 patients provided information about their age at diagnosis
  4. dCI and its severity are not clinically derived and are reliant on the responses of patients or caregivers
  5. Abbreviations: CI cognitive impairment, CNS central nervous system, MPS II mucopolysaccharidosis II, SD standard deviation